Merck & Co stops final-stage drug trial for treating PAH
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.
The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at.
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.
The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare and life-threatening genetic disease known as familial chylomicronemia.
Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.
Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood.
The US regulator has extended a review of an application by Organon & Co.’s atopic dermatitis (eczema) drug by three months with a.
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.